Effect of combined treatment with mirtazapine and risperidone on the MK-801-induced changes in the object recognition test in mice

Pharmacological Reports

Volumn 65, Issue 5, 2013, Pages 1401-1406

  Rogóz, Zofia ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Mice; Mirtazapine; MK 801; Object recognition test; Risperidone

Indexed keywords

DIZOCILPINE; DIZOCILPINE MALEATE; MIRTAZAPINE; RISPERIDONE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; LOCOMOTION; MALE; MEMORY CONSOLIDATION; MOUSE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PATTERN RECOGNITION; PERCEPTIVE DISCRIMINATION; SCHIZOPHRENIA; TRANQUILIZING ACTIVITY;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BRAIN; COGNITION; DIZOCILPINE MALEATE; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MIANSERIN; MICE; MOTOR ACTIVITY; RECEPTORS, N-METHYL-D-ASPARTATE; RECOGNITION (PSYCHOLOGY); RISPERIDONE;

EID: 84894166251     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/s1734-1140(13)71499-3     Document Type: Article

References (19)

1. Abbasi SH, Behpournia H, Ghoreshi A, Salehi B, Raznahan M, Rezazadeh SA, Rezaei F, Akhondzadeh S: The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double-blind randomized placebo-controlled trial. Schizophr Res, 2010, 116, 101-106.
2. Berk M, Gama C, Sundram S, Hustig H, Koopowitz L, D'Souza R, Malloy H et al.: Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomized, placebo-controlled clinical trial. Hum Psychopharmacol Clin Exp, 2009, 24, 233-238.
3. Burda K, Czubak A, Kuoe K, Nowakowska E, Ratajczak P, Zin J: Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats. Pharmacol Rep, 2011, 63, 898-907.
4. Cho SJ, Yook K, Kim B, Choi TK, Lee KS, Kim YW, Lee JE et al.: Mirtazapine augmentation enhances cognitive and reduced negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry, 2011, 35, 208-211.
5. Croom KF, Perry CM, Plosker GL: Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs, 2009, 23, 427-452.
6. de Lima MN, Laranja DC, Bromberg E, Roesler R, Schroder N: Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recog- nition memory in rats. Behav Brain Res, 2005, 156, 139-143. (Pubitemid 39330444)
7. Erhart SM, Marder SR, Carpenter WT: Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull, 2006, 32, 234-237.
8. Evins AE, Goff DC: Adjunctive antidepressant drug therapies in the treatment of negative symptoms of schizophrenia. CNS Drugs, 1996, 6, 130-147. (Pubitemid 26272980)
9. King MV, Sleight AJ, Woolley ML, Topham IA, Marsden CA, Fone KC: 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation-an effect sensitive to NMDA receptor antagonism. Neuropharmacology, 2004, 47, 195-204. (Pubitemid 38824643)
10. Nilsson M, Hansson S, Carlsson A, Carlsson ML: Differential effects of the N-methyl-D-aspartate receptor antagonists MK-801 on different stages of object recognition memory in mice. Neuroscience, 2007, 149, 123-130. (Pubitemid 47488657)
11. Nowakowska E, Kuoe K, Polañski A, Burda K, Nowakowska A, Sadowski C: Concomitant use of carbamazapine and olanzapine and the effect on some behavioral functions in rats. Pharmacol Rep, 2011, 63, 372-380.
12. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci, 2000, 68, 29-39.
13. Riedel G, Platt B, Micheau J: Glutamate receptor function in learning and memory. Behav Brain Res, 2003, 140, 1-47. (Pubitemid 36313239)
14. Rogó Z: Effect of co-treatment withmirtazapine and risperidone in animalmodel of the positive symptoms of schizophrenia inmice. Pharmacol Rep, 2012, 64, 1567-1572.
15. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl), 1996, 124, 57-73. (Pubitemid 26112775)
16. Sepehry AA, Potvin S, Elie R, Stip E: Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry, 2007, 68, 604-610. (Pubitemid 46663044)
17. Stahl SM: Stahl's Essential Psychopharmacology. 3rd edn., Cambridge University Press, New York, NY, 2008, 559-565.
18. Stenberg J-H, Terevnikov V, Joffe M, Tiihonen J, Tchoukhine E, Burkin M, Joffe G: More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 2011, 35, 1080-1086.
19. Terevnikov V, Stenberg JH, Tiihonen J, Joffe M, Burkin M, Tchoukhine E, Joffe G: Add-on mitrazapine improves depressive symptoms inschizophrenia: a double-blind placebo-controlled study with an open label extension phase. Hum Psychopharmacol, 2011, 26, 188-193.